Company / R&D per Share
Protalix BioTherapeutics, Inc. R&D per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.23
FY2025
5-year range
$0.23 / $1.28
FY2021-FY2025
Trend
-44.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has declined for 5 consecutive years, from $2.25 in FY2020 to $0.23 in FY2025.
Based on SEC 10-K filings.
0.23 in FY2025 with a 10-year CAGR of -3.2%.
Declined from $0.55 to $0.23 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -35.4%
- 5-Year CAGR
- -36.9%
- 10-Year CAGR
- -3.2%
Key checks
Key Insights
- Protalix BioTherapeutics, Inc.'s r&d per share has declined for 5 consecutive years.
- In FY2025, r&d per share decreased 44.0% year-over-year.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.23 | -44.0% |
| FY2024 | $0.40 | -27.2% |
| FY2023 | $0.55 | -34.0% |
| FY2022 | $0.84 | -34.7% |
| FY2021 | $1.28 | -42.9% |
| FY2020 | $2.25 | +3.6% |
| FY2019 | $2.17 | +981.3% |
| FY2017 | $0.20 | -26.8% |
| FY2016 | $0.27 | -12.2% |
| FY2015 | $0.31 | -20.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026